ACHV ACHIEVE LIFE SCIENCES, INC.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 949858 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-113.4%
TTM EPS YoY-4.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-104.2%
ROA-86.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio10.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-52.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | — | — | $5.32M | $6.71M | $7.10M | $7.30M |
| SG&A expense | — | — | — | — | $9.37M | $5.86M | $5.80M | $4.89M |
| Interest expense | $258,000 | $277,000 | $274,000 | $251,000 | $192,000 | $191,000 | $185,000 | $197,000 |
| Net income | -$12.11M | -$74.77M | -$10.17M | -$14.66M | -$14.44M | -$12.72M | -$12.83M | -$12.36M |
| EPS (basic) | -0.11 | -0.80 | -0.19 | — | -0.28 | -0.37 | -0.37 | — |
| EPS (diluted) | -0.11 | -0.80 | -0.19 | — | -0.28 | -0.37 | -0.37 | — |
| Weighted avg. shares (diluted) | 105.48M | 93.51M | 53.38M | — | 51.02M | 34.69M | 34.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $59.74M | $47.96M | $28.08M | $20.93M | $31.93M | $51.87M | $13.02M | $12.75M |
| Short-term investments | $141.78M | $139.34M | $1.19M | $15.47M | $16.18M | $3.52M | $10.23M | $21.61M |
| Current assets | $203.41M | $188.29M | $31.06M | $39.89M | $50.05M | $56.90M | $25.00M | $36.47M |
| PP&E, net | — | — | — | $3,000 | — | — | — | $8,000 |
| Goodwill | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M |
| Intangibles | $584,000 | $640,000 | $696,000 | $751,000 | $807,000 | $863,000 | $918,000 | $974,000 |
| Total assets | $206.42M | $190.44M | $33.10M | $41.79M | $52.04M | $58.94M | $27.36M | $38.63M |
| Current liabilities | $19.39M | $197.66M | $11.83M | $9.08M | $9.73M | $8.57M | $7.13M | $6.68M |
| Total liabilities | $25.69M | $205.12M | $22.43M | $20.27M | $18.43M | $17.27M | $17.08M | $17.73M |
| Shareholders' equity | $180.73M | -$14.68M | $10.68M | $21.52M | $33.62M | $41.67M | $10.28M | $20.90M |
| Shares outstanding | 109.78M | 102.72M | 53.24M | 53.23M | 52.81M | 49.69M | 34.69M | 34.69M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.36M | -$10.78M | -$6.93M | -$17.98M | -$11.33M | -$9.07M | -$11.09M | -$9.19M |
| Capital expenditure | $33,000 | — | — | — | — | — | — | — |
| Free cash flow | -$8.39M | — | — | — | — | — | — | — |
| Investing cash flow | -$1.66M | -$137.80M | $14.28M | $709,000 | -$12.65M | $6.70M | $11.35M | $11.72M |
| Financing cash flow | $21.58M | $168.46M | $21,000 | $6.26M | $4.04M | — | — | $682,000 |
| Depreciation & amortization | $63,000 | $58,000 | $57,000 | $57,000 | $54,000 | $55,000 | $62,000 | $58,000 |
| Stock-based compensation | $7.70M | $6.96M | -$685,000 | $1.30M | $2.34M | $2.89M | $2.23M | $1.24M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.